197 related articles for article (PubMed ID: 11535706)
1. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells.
Andriani F; Nan B; Yu J; Li X; Weigel NL; McPhaul MJ; Kasper S; Kagawa S; Fang B; Matusik RJ; Denner L; Marcelli M
J Natl Cancer Inst; 2001 Sep; 93(17):1314-24. PubMed ID: 11535706
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
3. Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB.
Zhang Y; Yu J; Unni E; Shao TC; Nan B; Snabboon T; Kasper S; Andriani F; Denner L; Marcelli M
Hum Gene Ther; 2002 Nov; 13(17):2051-64. PubMed ID: 12490000
[TBL] [Abstract][Full Text] [Related]
4. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo.
Zhang J; Thomas TZ; Kasper S; Matusik RJ
Endocrinology; 2000 Dec; 141(12):4698-710. PubMed ID: 11108285
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antitumor activity by probasin promoter-directed p202 expression.
Wen Y; Giri D; Yan DH; Spohn B; Zinner RG; Xia W; Thompson TC; Matusik RJ; Hung MC
Mol Carcinog; 2003 Jul; 37(3):130-7. PubMed ID: 12884364
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer.
Li X; Marani M; Yu J; Nan B; Roth JA; Kagawa S; Fang B; Denner L; Marcelli M
Cancer Res; 2001 Jan; 61(1):186-91. PubMed ID: 11196158
[TBL] [Abstract][Full Text] [Related]
7. Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer.
Furuhata S; Ide H; Miura Y; Yoshida T; Aoki K
Mol Ther; 2003 Mar; 7(3):366-74. PubMed ID: 12668132
[TBL] [Abstract][Full Text] [Related]
8. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
Warriar N; Pagé N; Koutsilieris M; Govindan MV
Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
11. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
13. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
[TBL] [Abstract][Full Text] [Related]
14. Androgen and its receptor promote Bax-mediated apoptosis.
Lin Y; Kokontis J; Tang F; Godfrey B; Liao S; Lin A; Chen Y; Xiang J
Mol Cell Biol; 2006 Mar; 26(5):1908-16. PubMed ID: 16479009
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
18. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
19. A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity.
Honda T; Kagawa S; Spurgers KB; Gjertsen BT; Roth JA; Fang B; Lowe SL; Norris JS; Meyn RE; McDonnell TJ
Cancer Biol Ther; 2002; 1(2):163-7. PubMed ID: 12170776
[TBL] [Abstract][Full Text] [Related]
20. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
